Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps
作者： Michael Block
DOI: 10.1517/17425255.2015.1037276
关键词:
摘要: Introduction: Modeling and simulation have become important means of answering questions relevant to the development a drug, making it possible assess risks early reduce costs. Physiologically based pharmacokinetic pharmacodynamic (PBPK/PD) models contribute comprehensive understanding covering specific from discovery through lifecycle management stages. As for other disease areas, in oncology, PBPK PD are topics that remain be addressed.Areas covered: This review describes current approaches, their applicability drug general specifically area oncology. It discusses status then focuses on key challenges potential future use. provides cases which modeling currently cannot answer assesses requirements close gaps PBPK/PD oncology.Expert opinion: led improvements identifying reducing costs du...
sci-hub.se 参考文章(82)
Andrea N Edginton, Stefan Willmann, Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clinical Pharmacokinectics. ,vol. 47, pp. 743- 752 ,(2008) , 10.2165/00003088-200847110-00005
Michelle Ghert, Nathan Evaniew, Isabella W.Y. Mak, Lost in translation: animal models and clinical trials in cancer treatment. American Journal of Translational Research. ,vol. 6, pp. 114- 118 ,(2014)
Kathleen P. Wilkie, A review of mathematical models of cancer-immune interactions in the context of tumor dormancy. Advances in Experimental Medicine and Biology. ,vol. 734, pp. 201- 234 ,(2013) , 10.1007/978-1-4614-1445-2_10
Kent Beck, M. Beedle, Arie Van Bennekum, Alistair Cockburn, W. Cunningham, Martin Fowler, James Grenning, Jim Highsmith, Andrew Hunt, Ron Jeffries, Jon Kern, Brian Marick, Robert C Martin, Steve Mellor, Ken Schwaber, Jeff Sutherland, Dave Thomas, Manifesto for agile software development The Agile Alliance, 2002-04. ,(2001)
Thomas Eissing, Jörg Lippert, Stefan Willmann, Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide Molecular Diagnosis & Therapy. ,vol. 16, pp. 43- 53 ,(2012) , 10.1007/BF03256429
Olaf Weber, Stefan Willmann, Hilmar Bischoff, Volkhart Li, Alexandros Vakalopoulos, Klemens Lustig, Frank-Thorsten Hafner, Roland Heinig, Carsten Schmeck, Klaus Buehner, Prediction of a potentially effective dose in humans for BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling British Journal of Clinical Pharmacology. ,vol. 73, pp. 219- 231 ,(2012) , 10.1111/J.1365-2125.2011.04064.X
Paul Polakis, Leslie A Khawli, Kedan Lin, C Andrew Boswell, Eduardo E Mundo, Ron Firestein, Crystal Zhang, Weiguang Mao, Herman Gill, Cynthia Young, Nina Ljumanovic, Shannon Stainton, Sheila Ulufatu, Aimee Fourie, Katherine R Kozak, Reina Fuji, An integrated approach to identify normal tissue expression of targets for antibody‐drug conjugates: case study of TENB2 British Journal of Pharmacology. ,vol. 168, pp. 445- 457 ,(2013) , 10.1111/J.1476-5381.2012.02138.X
Yuansheng Zhao, Zhe-Yi Hu, Physiologically based pharmacokinetic modelling and in vivo [I]/Ki accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate British Journal of Pharmacology. ,vol. 171, pp. 1043- 1053 ,(2014) , 10.1111/BPH.12533
Sravanthi Cheeti, Nageshwar R. Budha, Sharmila Rajan, Mark J. Dresser, Jin Y. Jin, A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer Biopharmaceutics & Drug Disposition. ,vol. 34, pp. 141- 154 ,(2013) , 10.1002/BDD.1830
Md L T Vieira, P Zhao, E G Berglund, K S Reynolds, L Zhang, L J Lesko, S-M Huang, Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clinical Pharmacology & Therapeutics. ,vol. 91, pp. 700- 708 ,(2012) , 10.1038/CLPT.2011.305